General MedicationsINTRAVENOUSGeneric
GIAPREZA
ANGIOTENSIN II ACETATE
Standard Dose
EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Discontinued
Summary
Approval overview GIAPREZA is listed in Drugs@FDA under application 209360 (NDA).
Review priority: PRIORITY Marketing status: Discontinued Active ingredient ANGIOTENSIN II ACETATE Form and strength SOLUTION;INTRAVENOUS - EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML) Sponsor LA JOLLA PHARMA Submission history Latest submission status date: 2017-12-21 00:00:00.
Structured Monograph
Clinical summary
Approval overview GIAPREZA is listed in Drugs@FDA under application 209360 (NDA). Review priority: PRIORITY Marketing status: Discontinued Active ingredient ANGIOTENSIN II ACETATE Form and strength SOLUTION;INTRAVENOUS - EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML) Sponsor LA JOLLA PHARMA Submission history Latest submission status date: 2017-12-21 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Discontinued
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.